Cargando…
Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model
The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951202/ https://www.ncbi.nlm.nih.gov/pubmed/35335618 http://dx.doi.org/10.3390/pathogens11030294 |
_version_ | 1784675327273861120 |
---|---|
author | Santiago, Helton C. Pereira-Neto, Tertuliano A. Gonçalves-Pereira, Marcela H. Terzian, Ana C. B. Durbin, Anna P. |
author_facet | Santiago, Helton C. Pereira-Neto, Tertuliano A. Gonçalves-Pereira, Marcela H. Terzian, Ana C. B. Durbin, Anna P. |
author_sort | Santiago, Helton C. |
collection | PubMed |
description | The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started to circulate in Latin America, and in 2016, ZIKV was considered by WHO to be a Public Health Emergency of International Concern due to cases of Congenital Zika Syndrome (CZS), a ZIKV-associated complication never observed before. After a peak of cases in 2016, the infection incidence dropped dramatically but still causes concern because of the associated microcephaly cases, especially in regions where the dengue virus (DENV) is endemic and co-circulates with ZIKV. A vaccine could be an important tool to mitigate CZS in endemic countries. However, the immunological relationship between ZIKV and other flaviviruses, especially DENV, and the low numbers of ZIKV infections are potential challenges for developing and testing a vaccine against ZIKV. Here, we discuss ZIKV vaccine development with the perspective of the immunological concerns implicated by DENV-ZIKV cross-reactivity and the use of a controlled human infection model (CHIM) as a tool to accelerate vaccine development. |
format | Online Article Text |
id | pubmed-8951202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89512022022-03-26 Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model Santiago, Helton C. Pereira-Neto, Tertuliano A. Gonçalves-Pereira, Marcela H. Terzian, Ana C. B. Durbin, Anna P. Pathogens Review The Zika virus (ZIKV) was first isolated from a rhesus macaque in the Zika forest of Uganda in 1947. Isolated cases were reported until 2007, when the first major outbreaks of Zika infection were reported from the Island of Yap in Micronesia and from French Polynesia in 2013. In 2015, ZIKV started to circulate in Latin America, and in 2016, ZIKV was considered by WHO to be a Public Health Emergency of International Concern due to cases of Congenital Zika Syndrome (CZS), a ZIKV-associated complication never observed before. After a peak of cases in 2016, the infection incidence dropped dramatically but still causes concern because of the associated microcephaly cases, especially in regions where the dengue virus (DENV) is endemic and co-circulates with ZIKV. A vaccine could be an important tool to mitigate CZS in endemic countries. However, the immunological relationship between ZIKV and other flaviviruses, especially DENV, and the low numbers of ZIKV infections are potential challenges for developing and testing a vaccine against ZIKV. Here, we discuss ZIKV vaccine development with the perspective of the immunological concerns implicated by DENV-ZIKV cross-reactivity and the use of a controlled human infection model (CHIM) as a tool to accelerate vaccine development. MDPI 2022-02-25 /pmc/articles/PMC8951202/ /pubmed/35335618 http://dx.doi.org/10.3390/pathogens11030294 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Santiago, Helton C. Pereira-Neto, Tertuliano A. Gonçalves-Pereira, Marcela H. Terzian, Ana C. B. Durbin, Anna P. Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title_full | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title_fullStr | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title_full_unstemmed | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title_short | Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model |
title_sort | peculiarities of zika immunity and vaccine development: lessons from dengue and the contribution from controlled human infection model |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951202/ https://www.ncbi.nlm.nih.gov/pubmed/35335618 http://dx.doi.org/10.3390/pathogens11030294 |
work_keys_str_mv | AT santiagoheltonc peculiaritiesofzikaimmunityandvaccinedevelopmentlessonsfromdengueandthecontributionfromcontrolledhumaninfectionmodel AT pereiranetotertulianoa peculiaritiesofzikaimmunityandvaccinedevelopmentlessonsfromdengueandthecontributionfromcontrolledhumaninfectionmodel AT goncalvespereiramarcelah peculiaritiesofzikaimmunityandvaccinedevelopmentlessonsfromdengueandthecontributionfromcontrolledhumaninfectionmodel AT terziananacb peculiaritiesofzikaimmunityandvaccinedevelopmentlessonsfromdengueandthecontributionfromcontrolledhumaninfectionmodel AT durbinannap peculiaritiesofzikaimmunityandvaccinedevelopmentlessonsfromdengueandthecontributionfromcontrolledhumaninfectionmodel |